Australian Clinical Labs

What Australian Clinical Labs does

Australian Clinical Labs (ASX: ACL) is one of Australia's largest private pathology services providers, operating a national diagnostic network through subsidiaries including Medlab Pathology, Gribbles, SunDoctors, SouthernSun Pathology, Specialised Trials, and BeFunctional. The company serves patients, general practitioners, specialists, and corporate clients across Australia and New Zealand, processing routine and specialized diagnostic tests through a distributed network of collection centers, accredited laboratories, and skin cancer clinics. Its portfolio spans hematology, biochemistry, microbiology, histopathology, dermatopathology, and clinical-trial central laboratory services.

The business model is anchored in Australia's Medicare-funded pathology framework: the majority of routine tests are bulk-billed to Medicare under the MBS, while specialized tests, pharmacogenomics, clinical trials, and corporate/insurance work are charged privately. Revenue is volume-driven and tied to GP referral volumes and seasonal disease cycles. In June 2026, ACL launched CNSDose — an exclusive Australian distribution partnership with Incite Genomics for a CYP2D6/CYP2C19-guided antidepressant/antipsychotic dosing test — marking its entry into pharmacogenomics. Operations are asset-heavy (collection network, accredited labs, courier logistics, IT), with significant fixed-cost exposure. The company is navigating recent setbacks including a 2023 ACCC-blocked A$1.58B bid for Healius, a 2022 Medlab Pathology ransomware attack (A$5.8M penalty, A$6.2M class-action settlement), a leadership transition (Melinda McGrath out, Greg Horan appointed June 2026), and a share buyback program covering up to 8.1 million shares announced October 2025.

Name

Australian Clinical Labs

Legal name

Australian Clinical Labs Limited

Website

https://clinicallabs.com.au

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Australian Clinical Labs is an ASX-listed private pathology provider operating a national network of diagnostic laboratories, collection centers, and skin cancer clinics across Australia and New Zealand, serving patients, GPs, and specialists through Medicare bulk billing and specialty private-pay testing.

Ownership category

akta.pro rank

Product category

Diagnostic Pathology Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Reference & Esoteric Testing Laboratories (HLAFAMAJ)

akta.pro secondary industries

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

Keywords

• Pathology diagnostic services
• Clinical laboratory testing
• Medical diagnostic services
• Genetic testing services
• Pathology collection centres

Headquarters

HQ city

Australian Capital Territory

HQ country

Australia

HQ region

Oceania

Offices6 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Medicare Bulk Billing Pathology Services: ACL primarily derives revenue from the public Medicare bulk billing system in Australia. The company provides pathology services bulk-billed to Medicare for eligible patients, with additional bulk-billed testing available under MBS items (e.g., HLA genotyping, HbA1c, genetic carrier screening). This represents the dominant revenue stream for the company's core diagnostic pathology services.
2. Private Pay Specialised Testing (CNSDose): Specialised tests such as CNSDose pharmacogenetic testing carry an out-of-pocket fee of $210, not covered by Medicare. Patients pay upfront via secure online portal. Some Medibank members with eligible mental health cover may claim a rebate. This represents a private-pay revenue stream for non-Medicare-rebatable tests.
3. Dividends to Shareholders: ACL distributes dividends to shareholders, including fully franked interim dividends (e.g., A$0.0375 per share declared for H1 2025 results). Dividend payments represent a return of capital to equity holders rather than a customer revenue stream.
4. Commercial/Workplace Pathology Services: ACL provides commercial services to employers including drug and alcohol testing, employee health screening, pre-employment screening, and insurance-related testing. These services are billed to corporate clients and employers under commercial contracts.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Australian Clinical Labs provides pathology diagnostic services across a national network of collection centres, delivering clinical pathology (haematology, biochemistry, microbiology, immunopathology), cytology, anatomical pathology, molecular genetics, and specialised genetic testing including the exclusive CNSDose pharmacogenetic test. Services are primarily bulk-billed through Medicare, with private-pay options for non-rebatable specialised tests and commercial workplace health offerings for employers.

Differentiator

Problem solved

Functional benefit

Brands

• CNSDose: Pharmacogenetic testing service for mental health medication optimization, developed in partnership with Incite Genomics
• Harmony NIPT
• Specialised Trials
• Gribbles
• SunDoctors
• SouthernSun Pathology
• BeFunctional

Products and services

• Australian Clinical Labs Pathology Services Comprehensive pathology diagnostic services including blood collection, clinical pathology testing (haematology, biochemistry, microbiology, immunopathology), cytology, anatomical pathology, and specimen processing across a national network of collection centres serving healthcare providers and patients in Australia and New Zealand.
• CNSDose Pharmacogenetic Testing Pharmacogenomic testing service analysing 19 genes involved in liver drug metabolism and blood-brain barrier transport to guide medication selection and dosing for mental health conditions including depression, anxiety, ADHD, and dementia. Covers 174 medications including 96 psychotropics. Available exclusively through ACL at A$210 out-of-pocket per test, with no Medicare rebate.
• Harmony Non-Invasive Prenatal Testing (NIPT) Targeted non-invasive prenatal testing (NIPT) screening for common fetal autosomal aneuploidies including Trisomy 21, 18, and 13. Available from 10 weeks of pregnancy for singleton and twin pregnancies, including IVF pregnancies with egg donors, offering high analytical sensitivity and specificity.
• Genetic Carrier Screening Bulk-billed genetic carrier screening for Cystic Fibrosis (CF), Spinal Muscular Atrophy (SMA), and Fragile X Syndrome (FXS) with 5–7 business day turnaround time from sample receipt, recommended for women and couples planning pregnancy under Medicare eligibility criteria.
• Pharmacogenetics (PGx) Panels Comprehensive pharmacogenetic testing covering cytochrome P450 enzymes (CYP2D6, CYP2C19, CYP2C9, CYP3A4, CYP3A5, CYP1A2, CYP2B6), VKORC1, SLCO1B1, UGT1A1, TPMT, DPYD and other genes to guide drug selection and dosing across mental health, cardiology, oncology, and pain management.
• EndoPredict Breast Cancer Recurrence Test Breast cancer recurrence risk test that analyses gene expression to help guide treatment decisions for early-stage breast cancer patients.
• Melaseq Melanoma Sequencing Melanoma sequencing test for solid tissue analysis supporting diagnosis and treatment decisions in skin cancer.
• Aspect Liquid Biopsy Liquid biopsy service for cancer testing using blood samples to detect genetic markers for oncology therapy selection and monitoring.
• Molecular Cancer Services Comprehensive molecular diagnostics service for cancer including genetic testing for oncology therapy selection, pharmacogenetics in oncology, and cancer genetics.
• Cervical Screening National Cervical Screening Program testing including HPV DNA primary testing with options for clinician-collected Liquid Based Cytology (LBC) and self-collected vaginal samples for eligible patients aged 25–74. Includes reflex cytology for HPV-positive non-16/18 results.
• Specialised Trials Clinical Trials Services Clinical trials services subsidiary providing pathology and diagnostic support for pharmaceutical and biotechnology clinical research studies, including specimen management and specialised diagnostic testing for clinical research.
• Commercial Drug & Alcohol Testing Workplace drug and alcohol testing services for employers including pre-employment screening, random testing, and post-incident testing, delivered under commercial contracts with corporate clients.
• Commercial Employee Health Screening Employee health screening services for corporate employers covering pre-employment medical assessments, employee wellness screening, and immunity screening.
• Environmental Water Testing Environmental screening services including biological monitoring and water testing for commercial and industrial clients.
• eResults Electronic Results Portal Electronic results portal allowing healthcare providers and patients to access pathology test results online, including downloadable CNSDose reports, with online billing and payment integration.
• eRequests Electronic Pathology Requesting Electronic pathology requesting system that enables clinicians to send pathology requests directly to patients' mobile via SMS, with native integration available for Best Practice, MedicalDirector Clinical, Genie, and Gentu practice management software.

Quantifiable outcome

• Recovery rates of 72% in CNSDose-guided prescribing compared to 28% with unguided prescribing in a randomised controlled trial.
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Incite GenomicscoreStrategic or Co-development Partner · 1 June 2026Australian Clinical Labs partnered with Incite Genomics to launch CNSDose, an innovative mental health pharmacogenetic test, nationally across ACL's network. ACL markets and distributes CNSDose through its extensive national network of clinicians, hospitals, and collection centres, significantly increasing access to this test throughout Australia. CNSDose was developed by Australian psychiatrists and represents a co-developed precision medicine capability brought to market through ACL's distribution infrastructure.
• Medlab PathologyminorOthersMedlab Pathology is a subsidiary of Australian Clinical Labs. In 2022, Medlab experienced a ransomware attack affecting over 223,000 individuals. ACL was ordered to pay A$5.8 million in civil penalties for this data breach under the Privacy Act — the first such penalty under Australian privacy law.
• Specialised TrialsminorOthersSpecialised Trials is a clinical trials services business operated by Australian Clinical Labs, providing pathology and diagnostic services supporting clinical research and medical research studies.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Sonic Healthcare: ASX-listed, Australia's largest pathology provider operating Sullivan Nicolaides Pathology and other lab brands. Direct competitor to ACL with national scale, GP referral model, and Medicare bulk-billing revenue.
• Healius (formerly Primary Health Care): ASX-listed pathology and diagnostic imaging provider operating Laverty Pathology and QML. Direct competitor and the company ACL tried to acquire for A$1.58B before the deal was blocked by the ACCC.
• Douglass Hanly Moir Pathology: Privately-held Australian pathology provider (Sonic subsidiary) operating in NSW. Directly comparable pathology services and customer base to ACL's operations.
• 4Cyte Pathology: Australian private pathology provider competing in bulk-billed GP-referred testing with a national footprint. Comparable operating model and customer segments to ACL.

Broad incumbents

• Quest Diagnostics: One of the world's largest clinical laboratory networks offering routine and esoteric diagnostics. Comparable in test menu breadth, reference lab operations, and specialty testing capabilities, though US-based and far larger scale.
• Laboratory Corporation of America (Labcorp): Global clinical laboratory and diagnostics leader with a broad routine and specialty test menu. Comparable as a large-scale commercial lab operator serving physicians, hospitals, and employers.
• ARUP Laboratories: US-based nonprofit reference laboratory specializing in esoteric and complex diagnostic testing. Comparable to ACL's reference lab function and growing specialty/esoteric mix.

Emerging players

• Myriad Genetics: US-based genetic testing company focused on hereditary cancer, pharmacogenomics, and molecular diagnostics. Comparable to ACL's EndoPredict, pharmacogenetics, and Aspect Liquid Biopsy offerings.
• NeoGenomics: US-based oncology-focused clinical laboratory offering molecular and genetic testing for cancer. Directly comparable to ACL's Molecular Cancer Services and oncology diagnostic portfolio.

Others

• Sonic Healthcare USA (including CPL, ProPath): International pathology operations of ACL's closest peer Sonic Healthcare, including CPL and ProPath labs. Comparable routine and esoteric pathology operations at a different geographic scope.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/australianclinicallabs
• LinkedInlinkedin.com/company/australian-clinical-labs

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Australian Clinical Labs